[ad_1] Eli Lilly, Novo Nordisk race to lock in India obesity drug market We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040,…
[ad_1] New Delhi: Pharma major Lupin Ltd on Thursday said its subsidiaries in the Philippines and Brazil have signed an exclusive licensing agreement with Italy’s Neopharmed Gentili S.p.A, for marketing and promotional rights for gastroenterology brand, Plasil in their respective markets. This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets,…
[ad_1] Lupin, Neopharmed sign licensing pact for Gastro brand Plasil in Brazil, Philippines We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Lupin receives positive EMA comittee opinion for eye therapy Ranluspec We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Lupin Nagpur injectable facility gets EIR from USFDA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Lupin Manufacturing Solutions, PolyPeptide Group forge long term Peptide alliance We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] New Delhi: Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic drug for the treatment of multiple sclerosis. The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Siponimod Tablets in strengths of…
[ad_1] Lupin secures tentative USFDA nod for multiple sclerosis drug Siponimod We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Lupin enter into licensing agreement with Valorum for biosimilar Armlupeg in US We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link